Rewind Therapeutics is a cutting-edge brand specializing in neuroscience and rare disease drug development. Led by a team of experienced scientists, entrepreneurs, and experts in their respective fields, Rewind Therapeutics is committed to advancing breakthrough therapeutics and treatments. Anja Harmeier, the Chief Executive Officer, brings extensive experience in R&D, company development, and venture capital.

Irene Knuesel, the Chief Scientific Officer, has a strong background in CNS research, drug discovery, and development. Christophe Van Vaeck, the Chief Financial Officer, has nearly 20 years of experience in the life sciences financial community. Guillaume Duvey, the Head of Medicinal Chemistry, has over 20 years of experience in small molecule drug discovery.

Ricardo Hermosilla, the Head of Translational Medicine, is a seasoned drug development expert with experience across multiple therapeutic areas. Finally, Stephen Burbidge, the Head of Research and Discovery, is an experienced drug hunter with expertise in small molecule and biological drug discovery. With a robust pipeline and a focus on innovation, Rewind Therapeutics is dedicated to bringing life-changing therapies to patients in need.

Their approach utilizes scientific expertise and strategic partnerships to drive the discovery and development of novel treatments. From rare diseases to neurodegenerative disorders, Rewind Therapeutics is at the forefront of pioneering advancements in medical research